Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.
OBJECTIVE
To explore the potential of dexrazoxane to suppress subclinical cardiotoxicity in MS patients receiving mitoxantrone.


METHODS
An open-label study was performed to evaluate possible subclinical cardiotoxicity in multiple sclerosis patients treated quarterly with mitoxantrone (48 mg/m(2) cumulative), with and without concomitant dexrazoxane, using blinded serial radionucleide ventriculography.


RESULTS
No patient experienced symptoms of heart failure. Patients receiving dexrazoxane, which is cardioprotective for anthracyclines, exhibited a significantly lesser decline in left ventricular ejection fraction (mean change, -3.80% vs -8.55%, p < 0.001).


CONCLUSIONS
These results support a cardioprotective effect of dexrazoxane in mitoxantrone treated multiple sclerosis patients.
Bernitsas
Evanthia
E
Department of Neurology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0322, USA.
Wei
Wei
W
Mikol
Daniel D
DD
D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity; D002317:Cardiovascular Agents / Q000378:metabolism / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000627:therapeutic use / Q000633:toxicity; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011929:Razoxane / Q000378:metabolism / Q000627:therapeutic use; D013318:Stroke Volume; D019210:Troponin I / Q000378:metabolism
D000970:Antineoplastic Agents; D002317:Cardiovascular Agents; D019210:Troponin I; D011929:Razoxane; D008942:Mitoxantrone